venBio Fund Trades 253,826 ALX Oncology Shares For A Pre-Funded Warrant, Goodman Filing Shows

Corey Goodman's group still reports 9.99% of ALX Oncology after the exchange, and its amended filing states no new demands.

Share
venBio Fund Trades 253,826 ALX Oncology Shares For A Pre-Funded Warrant, Goodman Filing Shows

Corey Goodman and the venBio entities he controls report a 9.99% stake, or 12,927,442 shares, in ALX Oncology in an amended ownership filing (Schedule 13D/A) made Friday. The filing also details an October 14 exchange in which a venBio fund gave up 253,826 common shares for a pre-funded warrant.

The exchange

Under the exchange agreement with ALX Oncology dated October 14, 2026, venBio Global Strategic Fund, L.P. agreed to surrender 253,826 common shares for no consideration. In return, the company agreed to issue a pre-funded warrant to buy up to 253,826 shares. The swap was expected to happen on or about October 15, subject to conditions in the agreement.

The warrant's exercise price is $0.001 per share. It can be exercised at any time after issuance, does not expire until exercised in full, and may be exercised on a cashless basis.

Exercise is blocked above a 9.99% ownership cap, counting the fund together with related parties. The fund can raise or lower the cap to as much as 19.99% by notice to the company, but an increase takes effect only on the 61st day after notice.

Who holds what

The 12,927,442-share total includes 129,260 shares issuable under the warrant, which the filing says is due to the 9.99% cap. Goodman is the sole director of the two general-partner companies above the funds, so he may be deemed to own what they hold.

venBio Global Strategic Fund II directly holds 8,453,038 shares, or 6.5% of the class, the largest single holding among the reporting persons. Fund I directly holds 3,715,963 shares plus the warrant for 253,826 shares, and venBio SPV, LLC holds 461,811 shares that Fund I may be deemed to own. Fund I's group is shown at 3.3%, or 4,307,034 shares.

Goodman may also be deemed to own 113,287 shares held by the Goodman Barinaga Trust, where he is trustee, and 54,083 shares held by Emaldi Corporation, where he is a director. No reporting person traded ALX Oncology securities in the past 60 days other than this exchange.

What Item 4 says

Item 4, the section where holders state their plans, incorporates the exchange and the joint filing agreement and adds one fact: Goodman resigned from the ALX Oncology board effective June 29, 2026. It states no demands, nominations or proposals.

The reporting persons signed a joint filing agreement on October 16, 2026. Robert Adelman, who has left the boards of the two general-partner companies, is no longer a reporting person. Shares closed at $1.06 on Friday, for a market value of $138 million.

The exchange and warrant terms were filed as exhibits to ALX Oncology's own current report dated October 15, 2026.

Sources

More on ALX Oncology Holdings

All ALX Oncology Holdings (ALXO) coverage →